Safety and immunogenicity of CoronaVac and ChAdOx1 heterologous prime-boost vaccines in an overweight population in Chiang Mai, Thailand

Background: In early 2021, the Ministry of Public Health of Thailand announced heterologous regimens for COVID-19 vaccines using CoronaVac as the first dose followed by ChAdOx1 nCoV-19 at 3 weeks apart. Priority was given to individuals above 60 years old and those who had seven underlying condition...

Fuld beskrivelse

Bibliografiske detaljer

Principais autores:	Kriangkrai Chawansuntati, Supachai Sakkhachornphop, Sayamon Hongjaisee, Saranta Freeouf, Patumrat Sripan, Nattaya Nusartsang, Romanee Chaiwarith, Tavitiya Sudjaritruk, Khuanchai Supparatpinyo, Jiraprapa Wipasa
Format:	Artigo
Sprog:	Inglês
Udgivet:	Elsevier 2024-06-01
Serier:	Vaccine: X
Fag:	Coronavirus disease (COVID-19) CoronaVac ChAdOx1 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Neutralizing antibodies
Online adgang:	http://www.sciencedirect.com/science/article/pii/S2590136224000482
Tags:	Tilføj Tag Ingen Tags, Vær først til at tagge denne postø!